CRO龙头康龙化成（300759）(300759.SZ)出圈了，原因竟是员工在办公室互殴。 近几日，网络上流传的视频显示，康龙化成的两名女员工在办公室大打出手，多名员工围观竟无人劝 阻。这一现象，引发市场对康龙化成公司文化的质疑。 康龙化成方面回应潇湘晨报称，这是员工排队之间的小矛盾，不影响公司经营。 康龙化成于2004年成立，2019年实现A股和H股上市，是一家全球领先的全流程一体化医药研发生产服 务平台。2021年，公司A股股价一度大涨26倍，市值逼近2000亿元。如今，公司市值约为468亿元，缩 水了1400多亿元。 与之对应的是，康龙化成的业绩增速放缓。根据最新发布的业绩预告，2025年上半年，公司预计实现归 母净利润约6.79亿元—7.13亿元，同比增长36%—39%，但经调整的非《国际财务报告准则》下归母净 利润同比增长仅为6%—11%。 康龙化成的股东频频减持。据不完全统计，公司股东通过减持累计套现超200亿元，其中，实际控制人 及一致行动人累计套现30亿元左右。 称员工打架同事围观为小事 康龙化成出圈，却源于员工在办公室互殴，引发了市场质疑。 近日有多位网友发帖，称在康龙化成北京一园区有两个女 ...

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]